Canada Markets open in 7 hrs 58 mins

Scipher Medicine Appoints Dr. Michael Elliott to its Science Advisory Board

·3 min read

Industry Pioneer and Former Senior Vice President of Immunology at Janssen Pharmaceuticals Brings Decades of Experience in Autoimmune Diseases to Fast-Growing Precision Immunology Company

WALTHAM, Mass., December 02, 2021--(BUSINESS WIRE)--Scipher Medicine, a precision immunology company matching patients with their most effective therapy, today announced the appointment of Michael Elliott, MBBS, PhD, FRACP, as scientific advisor. Dr. Elliott is a physician-scientist and pioneer in drug development for autoimmune diseases.

This press release features multimedia. View the full release here:

Michael Elliott, MBBS, PhD, FRACP, Scipher Medicine, Scientific Advisor (Photo: Business Wire)

Dr. Elliott’s career spans 25 years including his role as senior vice president of Immunology at Janssen Pharmaceuticals, a Johnson & Johnson company, where he led the clinical development of Remicade® (infliximab), Simponi® (golimumab) and Stelara® (ustekinumab) for the treatment of rheumatoid arthritis (RA) and other autoimmune diseases.

Earlier in his career, at the Kennedy Institute of Rheumatology in London, Dr. Elliott worked on the earliest clinical trials of anti-tumor necrosis factor (TNF) therapy in RA and was first author on several acclaimed publications that provided clinical validation for this then-new approach to treatment.

"I’m excited to join Scipher Medicine and support its important mission to match patients with their most effective therapy," said Dr. Elliott. "Anti-TNF therapy was a radical new approach to treatment of autoimmune disease in its time. Fast forward to today, Scipher Medicine is ushering in a new era using its Spectra platform to enable precision medicine across several autoimmune diseases."

"We are thrilled to welcome Dr. Elliott to our science advisory board," said Alif Saleh, Chief Executive Officer of Scipher Medicine. "As a pioneer in our field he has a keen understanding of how scientific advancements can transform clinical care to the benefit of patients."

Dr. Elliott earned his medical degree (MBBS) and PhD in Immunology from the University of Adelaide, Australia, and was elected a Fellow of the Royal Australasian College of Physicians.

About Scipher Medicine®

Scipher Medicine, a precision immunology company matching patients with their most effective therapy, believes that patients deserve simple answers to treatment options based on scientific data. Using Spectra™, our proprietary network medicine platform, we commercialize tests revealing a person’s unique molecular disease signature and match it to the most effective therapy, ensuring optimal treatment from day one. The patient molecular data generated from our tests further supports the discovery and development of novel and more effective therapeutics. We partner with leading payers, health care providers, and pharmaceutical companies to bring solutions to patients with autoimmune diseases. Visit and follow Scipher Medicine on Twitter, Facebook, and LinkedIn.

About PrismRA®

PrismRA is a revolutionary blood test bringing precision medicine to the treatment of rheumatoid arthritis, which affects 20 million patients globally. From a routine blood draw, the PrismRA test analyzes an individual’s molecular signature, helping identify who is unlikely to adequately respond to TNFi therapy, the world’s largest selling drug class, so non-responders can be prescribed alternative effective therapy and avoid unnecessary dose escalations or drug cycles. Providers now have objective data to guide therapeutic decision-making and give patients the best chance of achieving treatment targets and improving clinical outcomes. For more information, please visit

View source version on


Media Relations
Matt Burns
VP, Head of Communications

Investor Relations
John Strumbos, Ph.D., MBA
Chief Financial Officer

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting